GI Genius Module 100 (GGM100.US); GI Genius Module 200 (GGM200.US); ColonPRO 4.0 (CPRO40.US); GI Genius Module 300 (GGM300-US); ColonPRO 4.0 (CPRO40S-US)

The GI Genius™ system employs advanced artificial intelligence, specifically convolutional neural networks, to provide real-time analysis of colonoscopy video feeds, aiding clinicians in the detection of polyps and adenomas. Clinical evidence supports its efficacy in significantly increasing the Adenoma Detection Rate and reducing miss rates, thereby enhancing the quality and effectiveness of colorectal cancer screening procedures.

The GI Genius™ system is an artificial intelligence-powered tool designed to enhance colorectal screening by improving the detection of polyps and lesions during colonoscopies. It integrates seamlessly with standard colonoscopy equipment, utilizing its ColonPRO™ 4.0 software to analyze live video feeds in real time. The system provides immediate visual cues by highlighting suspicious areas with on-screen green boxes and an audible alert, thereby assisting clinicians in identifying potential abnormalities that might otherwise be missed and standardizing quality metrics such as the Adenoma Detection Rate (ADR). The underlying technology of GI Genius™ relies on sophisticated convolutional neural networks (CNNs) trained extensively on a vast dataset of colonoscopy images. A recent July 2024 update introduced software version 4.0 running on new sixth-generation hardware, which incorporates advanced NVIDIA IGX Orin–based processing for enhanced performance. Clinical studies have robustly demonstrated the system's benefits, with prospective trials showing a significant increase in ADR (e.g., 54.8% with GI Genius versus 40.4% with standard colonoscopy) and a notable reduction in the adenoma miss rate, underscoring its value as an adjunctive tool in improving the efficacy of colonoscopic examinations. The device is CE-marked, received FDA clearance in 2021, and is marketed by Medtronic in the U.S.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the performance of GI Genius™ (ColonPRO™ 4.0) vary with different polyp morphologies, sizes, and locations within the colon?; What is the learning curve for endoscopists using the GI Genius™ system, and does its use significantly alter procedure duration or patient discomfort?; Are there studies comparing the long-term impact on colorectal cancer incidence and mortality in populations screened with GI Genius™ versus standard colonoscopy?; How does the NVIDIA IGX Orin–based processing in the sixth-generation hardware specifically improve the real-time analytical capabilities or reduce latency compared to previous versions?; What strategies are in place to continuously update the convolutional neural network training data to account for new imaging modalities or rare pathological findings?